en · de · es · fr · pt
hplc-notes.peptides5388.com › Topic › Discovery And Receptor Profile — Worked Examples

Discovery And Receptor Profile — Worked Examples

By Editorial Desk · published 2025-09-25 · last reviewed 2025-11-07 · Topic

If you have been reading about 肽类药物 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

Discovery and Receptor Profile

Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.

Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.

Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.

三重受体激动剂的分子设计

retatrutide 是一种人工合成的多肽,设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子,而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础,经过非天然氨基酸替换和脂肪酸侧链修饰,以获得更长的作用时间。该方向属于多受体激动剂研究的一部分,与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同:GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节,胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应,也可能出现相互制约,具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标,但协同关系的细节仍处在研究阶段。

Retatrutide at a glance

PropertyValueNotes
Molecular classSynthetic peptideContains non-natural residues
Receptor targetsGLP-1, GIP, glucagonTriple agonist profile
Route of administrationSubcutaneous injectionIn clinical trial settings
Development statusInvestigationalNot approved in major markets
Approximate molecular massAbout 4.7 kDaPeptide-scale molecule

Reference notes

Vitamin B12 is absorbed by a B12-specific transport proteins or via passive diffusion. Transport-mediated absorption and tissue delivery is a complex process involving three transport proteins: haptocorrin (HC), intrinsic factor (IF) and transcobalamin II (TC2), and respective membrane receptor proteins (Figure). HC is present in saliva. As vitamin-containing food is digested by hydrochloric acid and pepsin secreted into the stomach, HC binds the vitamin and protects it from acidic degradation. Upon leaving the stomach the hydrochloric acid of the chyme is neutralized in the duodenum by bicarbonate, and pancreatic proteases release the vitamin from HC, making it available to be bound by IF, which is a protein secreted by gastric parietal cells in response to the presence of food in the stomach. IF delivers the vitamin to receptor proteins cubilin and amnionless, which together form the cubam receptor in the distal ileum. The receptor is specific to the IF-B12 complex, and so will not bind to any vitamin content that is not bound to IF. Investigations into the intestinal absorption of B12 confirm that the upper limit of absorption per single oral dose is about 1.5 μg, with 50% efficiency. In contrast, the passive diffusion process of B12 absorption — normally a small portion of total absorption of the vitamin from food consumption — may exceed the haptocorrin- and IF-mediated absorption when oral doses of B12 are large, with roughly 1% efficiency.

Tunable metamaterials allow arbitrary adjustments to frequency changes in the refractive index. A tunable metamaterial expands beyond the bandwidth limitations in left-handed materials by constructing various types of metamaterials.

The first element of the system is the amino acid that is added to the genetic code of a certain strain of organism. Over 71 different NSAAs have been added to different strains of E. coli, yeast or mammalian cells. Due to technical details (easier chemical synthesis of NSAAs, less crosstalk and easier evolution of the aminoacyl-tRNA synthase), the NSAAs are generally larger than standard amino acids and most often have a phenylalanine core but with a large variety of different substituents. These allow a large repertoire of new functions, such as labeling (see figure), as a fluorescent reporter (e.g. dansyl alanine) or to produce translational proteins in E. coli with Eukaryotic post-translational modifications (e.g. phosphoserine, phosphothreonine, and phosphotyrosine). The founding work was performed by Rolf Furter, who used the yeast tRNAPhe/PheRS pair to incorporate p-fluorophenylalanine in E. coli.

Sources: en.wikipedia.org

Related pages on this site

Reference notes

==== Intelligence ==== It is unclear whether breastfeeding improves intelligence later in life. Several studies found no relationship after controlling for confounding factors like maternal intelligence (smarter mothers were more likely to breastfeed their babies). However, other studies concluded that breastfeeding was associated with increased cognitive development in childhood, although the cause may be increased mother–child interaction rather than nutrition.

In analysis of biological systems, inorganic salts, which are also part of protein extracts, interfere with the ionization process. The salts can be removed by solid phase extraction or by washing the dried-droplet MALDI spots with cold water. Both methods can also remove other substances from the sample. The matrix-protein mixture is not homogeneous because the polarity difference leads to a separation of the two substances during co-crystallization. The spot diameter of the target is much larger than that of the laser, which makes it necessary to make many laser shots at different places of the target, to get the statistical average of the substance concentration within the target spot.

== Clinical significance == AST is similar to alanine transaminase (ALT) in that both enzymes are associated with liver parenchymal cells. The difference is that ALT is found predominantly in the liver, with clinically negligible quantities found in the kidneys, heart, and skeletal muscle, while AST is found in the liver, heart (cardiac muscle), skeletal muscle, kidneys, brain, and red blood cells. As a result, ALT is a more specific indicator of liver inflammation than AST, as AST may be elevated also in diseases affecting other organs, such as myocardial infarction, acute pancreatitis, acute hemolytic anemia, severe burns, acute renal disease, musculoskeletal diseases, and trauma. The elevated AST level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate. AST was defined as a biochemical marker for the diagnosis of acute myocardial infarction in 1954. However, the use of AST for such a diagnosis is now redundant and has been superseded by the cardiac troponins. Laboratory tests should always be interpreted using the reference range from the laboratory that performed the test. Example reference ranges are shown below:

Sources: en.wikipedia.org

Frequently asked questions

What receptors does retatrutide target?

It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.

Has retatrutide been approved for use?

No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.

How does it differ from dual-agonist compounds?

The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.

三重激动指的是什么?

指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。

Network